Lundbeck to Acquire Prexton Therapeutics

Lundbeck to Acquire Prexton Therapeutics
Lundbeck to Acquire Prexton Therapeutics

Danish drugmaker Lundbeck has announced plans to buy Swiss drug developer Prexton Therapeutics in a deal worth up to €905 million.

The deal would give Lundbeck global rights to Prexton’s foliglurax, a first-in-class experimental therapy for Parkinson’s disease that is currently in Phase II trials. First data from the clinical Phase II program is expected to be available in mid-2019.

Foliglurax works by stimulating a specific glutamatergic target that actives a compensatory neuronal system in the brain. The aim is to treat the motor systems of Parkinson’s, such as resting tremor and dyskinesia.  Lundbeck said pre-clinical studies have demonstrated positive effects in models of the neurological condition, which affects around 6 million people worldwide.

Under the terms of the agreement, Lundbeck will pay €100 million upfront to Prexton, plus up to €805 million on development, regulatory and sales milestones

M-Ventures, the corporate venture arm of Germany’s Merck KGaA, co-founded Prexton in 2012 with Francois Conquet, formerly director, licensing and business development at Merck Serono and CEO/founder of Addex Therapeutics. Prexton said it applies a new scientific approach that fully integrates molecular, behavioral and chemistry technologies to address Parkinson’s disease and other brain disorders.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.